Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
698.25
-14.62 (-2.05%)
At close: May 15, 2026, 4:00 PM EDT
697.16
-1.09 (-0.16%)
After-hours: May 15, 2026, 7:51 PM EDT
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,410 employees as of December 31, 2025. The number of employees increased by 304 or 2.01% compared to the previous year.
Employees
15,410
Change (1Y)
304
Growth (1Y)
2.01%
Revenue / Employee
$968,177
Profits / Employee
$287,047
Market Cap
71.04B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15,410 | 304 | 2.01% |
| Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
| Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
| Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
| Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
| Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
| Dec 31, 2019 | 8,100 | 700 | 9.46% |
| Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
| Dec 31, 2017 | 6,200 | 800 | 14.81% |
| Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
| Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
| Dec 31, 2014 | 2,925 | 585 | 25.00% |
| Dec 31, 2013 | 2,340 | 390 | 20.00% |
| Dec 31, 2012 | 1,950 | 246 | 14.44% |
| Dec 31, 2011 | 1,704 | 309 | 22.15% |
| Dec 31, 2010 | 1,395 | 366 | 35.57% |
| Dec 31, 2009 | 1,029 | 110 | 11.97% |
| Dec 31, 2008 | 919 | 237 | 34.75% |
| Dec 31, 2007 | 682 | 109 | 19.02% |
| Dec 31, 2006 | 573 | -15 | -2.55% |
| Dec 31, 2005 | 588 | -142 | -19.45% |
| Dec 31, 2004 | 730 | 86 | 13.35% |
| Dec 31, 2003 | 644 | -25 | -3.74% |
| Dec 31, 2002 | 669 | 94 | 16.35% |
| Dec 31, 2001 | 575 | 84 | 17.11% |
| Dec 31, 2000 | 491 | 54 | 12.36% |
| Dec 31, 1999 | 437 | 66 | 17.79% |
| Dec 31, 1998 | 371 | 101 | 37.41% |
| Dec 31, 1997 | 270 | 27 | 11.11% |
| Dec 31, 1996 | 243 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Vertex Pharmaceuticals | 6,400 |
| Moderna | 4,700 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
REGN News
- 12 hours ago - Regeneron announces Phase 3 trial of fianlimab did not reach primary endpoint - TheFly
- 2 days ago - Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma - GlobeNewsWire
- 2 days ago - UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair - GlobeNewsWire
- 2 days ago - Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair - GlobeNewsWire
- 5 days ago - Regeneron Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 9 days ago - Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years - GlobeNewsWire
- 12 days ago - Regeneron, Sanofi present results from Dupixent Phase 4 trial - TheFly
- 12 days ago - Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial - GlobeNewsWire